CoLucid Pharmaceuticals shares are up ~290% YTD, and I think that's just the beginning.

Abilify is the single best-selling CNS drug of all time, but it's clearly not perfect. VistaGen Therapeutics looks to build upon the success of Abilify with a new approach to neurological disorders with Phase 2 candidate, AV101.

HedgePath Pharma reported interim results from its ongoing Phase 2b data in patients with Basal Cell Carcinoma Nevus Syndrome.

This is a transcript of an interview I did with the management team at Relmada Therapeutics.

On October 13, 2016, Can-Fite Biopharma Ltd (CANF) announced it has submitted the clinical trial protocol for its Phase II study of CF102 in the treatment of NAFLD, the precursor to NASH, to a leading Institutional Review Board (IRB) in Israel.

Several biopharma companies are working on therapeutic agents for AML that target CD33, including Amgen, Bayer, Boehringer Ingelheim, and J&J. However, only Actinium and Seattle Genetics (SGEN) have progressed beyond Phase 1 studies.